Xtandi 80 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FJQC3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,255
Award facts
- Contract value 100% obligated
- $4,255.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $4,255.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count units). The award, issued on December 19, 2025, with an ultimate completion date of December 22, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a ceiling value of $499,999,999 and completion date of December 31, 2036.
The PPV-G GEN V represents part of the broader $30.3 billion acquisition strategy designed to supply pharmaceutical products to Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group serves as a regional prime vendor contractor authorized to provide branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support recurring military medical supply needs. Xtandi, an oncology treatment, falls within the company's established product portfolio of specialized pharmaceuticals. The vendor has demonstrated substantial federal contracting capability through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division, with no subcontractor relationships identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FJQC3?
SPE2DR26FJQC3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 19, 2025.
How much is contract SPE2DR26FJQC3 worth?
The government has obligated $4,255 on SPE2DR26FJQC3.
Is contract SPE2DR26FJQC3 an order under another contract?
Yes. SPE2DR26FJQC3 is a delivery order under SPE2DR25D9224, an indefinite delivery contract.
Was contract SPE2DR26FJQC3 competed?
The extent of competition for SPE2DR26FJQC3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award